)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Anbio Biotechnology
Anbio Biotechnology (NNNN) investor relations material
Anbio Biotechnology Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary7 Apr, 2026
Executive summary
Revenue for 2025 was $8.65 million, up 5.6% from 2024, with gross profit of $7.54 million and net income of $6.40 million, reflecting a significant shift to non-COVID IVD products (80.4% of revenue in 2025).
Gross margin improved to 87.2% in 2025 from 71.9% in 2024, driven by a higher-margin product mix and cost controls.
The company completed its IPO in February 2025, raising $8 million in gross proceeds.
Operations are primarily conducted through a Samoa subsidiary, with a global sales footprint and a focus on regulatory compliance for IVD products.
Financial highlights
Revenue: $8.65M (2025), $8.19M (2024), $6.71M (2023); 2025 revenue up 5.6% YoY, 2024 up 21.9% YoY.
Gross profit: $7.54M (2025), $5.89M (2024), $3.36M (2023); gross margin rose to 87.2% in 2025.
Net income: $6.40M (2025), $2.37M (2024), $2.25M (2023); net income up 169.9% YoY in 2025.
SG&A expenses dropped 54% in 2025 due to lower professional fees post-IPO and cost controls.
R&D expenses decreased to $201K in 2025 as products matured and required less development.
Cash and equivalents at year-end 2025: $7.77M; working capital: $30.16M.
Outlook and guidance
Management expects continued growth in non-COVID IVD products and further market expansion.
Focus on regulatory approvals (IVDR in EU, FDA in US) and diversification into new diagnostic segments.
Sufficient cash and IPO proceeds to fund operations and expansion for at least 12 months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Anbio Biotechnology
- Net income and gross margin rose despite lower revenue, driven by a shift to non-COVID diagnostics.NNNN
Q2 202516 Jun 2026 - IPO targets global diagnostics growth, but faces customer concentration and dual-class risks.NNNNRegistration filing16 Jun 2026
- IPO targets $7M for global IVD expansion, with growth in non-COVID products and key governance risks.NNNNRegistration filing16 Jun 2026
- 2024 revenue rose 21.9% to $8.19M, with gross margin at 71.9% and net income of $2.37M.NNNNQ4 202416 Jun 2026
- Planned IPO with recent capital raises, governance structures, and a waiver for financial statement timing.NNNNRegistration filing16 Jun 2026
- Proposed public offering features multi-class shares, audited financials, and emerging growth status.NNNNRegistration filing16 Jun 2026
Anbio Biotechnology
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage